“Our chances of creating and deploying an effective vaccine have never been greater, neither for Europeans here at home nor for the rest of the world,” said European Commission President Ursula von der Leyen.
“To defeat the coronavirus anywhere, you’ll have to defeat it everywhere. “
Brussels has signed agreements with Sanofi-GSK, Johnson
“We are confident that among these applicants there will be an effective vaccine opposed to COVID-19 to help us overcome this pandemic,” said EU Health Commissioner Stella Kyriakides.
In a statement, BioNTech said the agreement includes an option for another hundred million doses.
Deliveries can begin by the end of 2020, if laboratories effectively pass the testing stages.
“We have activated our chain of origin, especially our site in Belgium, and are starting to manufacture to make our vaccine available as temporarily as possible, if our clinical trials are successful and regulatory approval is granted,” Albert Bouria said. , President and CEO of Pfizer.
Laboratories around the world are rushing to produce a vaccine to end the worst fitness crisis in more than a century.
More than two hundred candidate vaccines have been developing lately, of which about two dozen are in clinical trials with human volunteers.
Countries have also sought sufficient doses, and the world’s richest countries place billions of dollars of advance orders for safe deliveries even before vaccines have finished testing.
Amid considerations that U. S. President Donald Trump will pressure regulators to pass a vaccine before the November presidential election, corporate CEOs, adding BioNTech and Pfizer, pledged this week to “maintain the integrity of the clinical process. “